InvestorsHub Logo
Followers 51
Posts 9144
Boards Moderated 1
Alias Born 10/25/2007

Re: Civil War General post# 12252

Monday, 12/12/2022 11:37:25 PM

Monday, December 12, 2022 11:37:25 PM

Post# of 13523
The U.S. FDA has cleared an Investigational New Drug application by
Vertex Pharma
for VX-522, an mRNA therapy targeted at treating the underlying cause of CysticFibrosis, for people who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator.

VX-522 is the result of an exclusive research collaboration between Vertex and Moderna. VX-522 is delivered to the lung through inhalation of a CFTR mRNA encapsulated by a lipid nanoparticle, and the mRNA is designed to produce functional copies of the CFTR protein.

https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-investigational-new-drug-ind-application-vx-522
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News